Final answer:
Dantrolene is used to treat malignant hyperthermia (MH) with an initial dose of 2.5 mg/kg for adults, with additional doses as required up to a maximum of 10 mg/kg, guided by the patient's response.
Step-by-step explanation:
The dosing of dantrolene for the treatment of malignant hyperthermia (MH) is critical for the successful management of this life-threatening condition. Generally, the initial dose of dantrolene for an adult is 2.5 mg/kg, given intravenously. If the signs of MH continue, additional doses as needed may be administered, with a recommended maximum cumulative dose of 10 mg/kg. As always, dosing should be guided by the patient's response, and careful monitoring is essential. Due to dantrolene's specificity in treating MH, early identification and treatment of the condition are vital, and all medical personnel involved in the administration of anesthesia should be knowledgeable about the rapid recognition and management of MH.